Our results may facilitate selection of suitable candidates for this type of therapy even though previous studies of adjuvant chemotherapy ranged from stage I to III NSCLC with KRAS and TP53 co‐mutations could not prove clinical benefit,33, 34 while patients with these co‐mutations might have predictive value of immunotherapy35 through increased expression of PD‐L1 and mutation burden.36 This evidence concerns the gene TP53 and non-small cell lung carcinoma.